Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Politics
Anna Bawden Health and social affairs correspondent

Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

Pack of Wegovy next to injection pens
Researchers found that among a number of drugs Wegovy had the strongest association with sudden vision loss. Photograph: James Manning/PA

Patients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines such as semaglutide (sold as Wegovy, Ozempic and Rybelsus) and tirzepetide (sold as Mounjaro) help reduce blood sugar levels, slow digestion and reduce appetite, and have been linked to reduced risks of heart attack, fewer drug overdoses and other health benefits.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.